The CathPilot: Performance Validation and Preclinical Safety and Feasibility Assessment

被引:4
|
作者
Zhou, James J. [1 ]
Alawneh, Yara [1 ]
Sewani, Alykhan [1 ]
Keshavarz, Mohammadmahdi [1 ]
Tahmasebi, Mohammadmahdi [1 ]
Roy, Trisha [3 ]
Kayssi, Ahmed [4 ,5 ]
Dueck, Andrew [4 ,5 ]
Wright, Graham A. [4 ,5 ]
Tavallaei, M. Ali [2 ]
机构
[1] Toronto Metropolitan Univ, Toronto, ON, Canada
[2] Toronto Metropolitan Univ, Toronto, ON M5B 2K3, Canada
[3] Houston Methodist, Houston, TX 77030 USA
[4] Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada
[5] Univ Toronto, Toronto, ON, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Catheters; Lesions; Navigation; Visualization; Phantoms; Safety; Arteries; Peripheral vascular interventions; angioplasty; atherectomy; non-steerable catheter; steerable catheter; catheter navigation; catheter manipulation; catheter limitations; peripheral artery disease; chronic total occlusions; guidewires; endovascular; CathPilot; MECHANICAL-PROPERTIES; SEVERE ISCHEMIA; LEG BASIL; ANGIOPLASTY; GUIDEWIRE; BYPASS; REVASCULARIZATION; FAILURE; DISEASE;
D O I
10.1109/TBME.2023.3276199
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
<bold>Objectives</bold>: Peripheral endovascular revascularization procedures often fail due to technical limitations of guidewire support, steering, and visualization. The novel CathPilot catheter aims to address these challenges. This study assesses the safety and feasibility of the CathPilot and compares its performance to conventional catheters for peripheral vascular interventions. <bold>Methods</bold>: The study compared the CathPilot to non-steerable and steerable catheters. The success rates and access times for a relevant target inside a tortuous vessel phantom model were assessed. The reachable workspace within the vessel and the guidewire's force delivery capabilities were also evaluated. To validate the technology, chronic total occlusion tissue samples were used ex vivo to compare crossing success rates with conventional catheters. Finally, in vivo experiments in a porcine aorta were conducted to evaluate safety and feasibility. <bold>Results</bold>: The success rates for reaching the set targets were 31%, 69%, and 100% with the non-steerable catheter, the steerable catheter, and the CathPilot, respectively. CathPilot had a significantly larger reachable workspace, and allowed for up to four times higher force delivery and pushability. In crossing of chronic total occlusion samples, the CathPilot achieved a success rate of 83% and 100%, for fresh and fixed lesions respectively, which was also significantly higher than conventional catheters. The device was fully functional in the in vivo study, and there were no signs of coagulation or damage to the vessel wall. <bold>Conclusion</bold>: This study shows the safety and feasibility of the CathPilot system and its potential to reduce failure and complication rates in peripheral vascular interventions. The novel catheter outperformed conventional catheters in all defined metrics. This technology can potentially improve the success rate and outcome of peripheral endovascular revascularization procedures.
引用
收藏
页码:3116 / 3125
页数:10
相关论文
共 50 条
  • [1] Ablating Myocardium Using Nanosecond Pulsed Electric Fields: Preclinical Assessment of Feasibility, Safety, and Durability
    Nies, Moritz
    Watanabe, Keita
    Kawamura, Iwanari
    Wang, Bingyan J.
    Litt, Jeffrey
    Turovskiy, Roman
    Danitz, David J.
    Uecker, Darrin R.
    Linder, Keith E.
    Maejima, Yasuhiro
    Sasano, Tetsuo
    Reddy, Vivek Y.
    Koruth, Jacob S.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2024, 17 (07):
  • [2] Validation and Performance Assessment of a Preclinical SiPM-Based SPECT/MRI Insert
    Carminati, M.
    Baratelli, F. M.
    Occhipinti, M.
    Erlandsson, K.
    Nagy, K.
    Nyitrai, Z.
    Czeller, M.
    Kuehne, A.
    Niendorf, T.
    Valtorta, S.
    Belloli, S.
    Moresco, R. M.
    Savi, A.
    Iadanza, A.
    Falini, A.
    Politi, L. S.
    Cadioli, M.
    Hutton, B. E.
    Fiorini, C.
    IEEE TRANSACTIONS ON RADIATION AND PLASMA MEDICAL SCIENCES, 2019, 3 (04) : 483 - 490
  • [3] Preclinical cardiac safety assessment of drugs
    Hanton G.
    Drugs in R & D, 2007, 8 (4) : 213 - 228
  • [4] FAMOTIDINE - SUMMARY OF PRECLINICAL SAFETY ASSESSMENT
    BUREK, JD
    MAJKA, JA
    BOKELMAN, DL
    DIGESTION, 1985, 32 : 7 - 14
  • [5] Preclinical safety assessment of aqueous fern extracts
    Lauer, L.
    Zilkowski, I.
    Bertrams, J.
    Turek, C.
    Mueller, M. B.
    Moerbt, N.
    Voegele, P.
    Stintzing, F. C.
    TOXICOLOGY LETTERS, 2019, 314 : S130 - S130
  • [6] Status of preclinical safety assessment for immunomodulatory biopharmaceuticals
    Green, JD
    Black, LE
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (04): : 208 - 212
  • [7] Validation of the Surrogate Safety Assessment Model for Assessment of Intersection Safety
    Vasconcelos, Luis
    Neto, Luis
    Seco, Alvaro Maia
    Silva, Ana Bastos
    TRANSPORTATION RESEARCH RECORD, 2014, (2432) : 1 - 9
  • [8] IRON PROTEIN SUCCINYLATE - PRECLINICAL SAFETY ASSESSMENT
    FORSTER, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1993, 31 (02) : 53 - 60
  • [9] Preclinical safety assessment:: In vitro -: in vivo testing
    Hojelse, F
    PHARMACOLOGY & TOXICOLOGY, 2000, 86 : 6 - 7
  • [10] Perspectives of data science in preclinical safety assessment
    Steger-Hartmann, Thomas
    Kreuchwig, Annika
    Wang, Ken
    Birzele, Fabian
    Draganov, Dragomir
    Gaudio, Stefano
    Rothfuss, Andreas
    DRUG DISCOVERY TODAY, 2023, 28 (08)